本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物:SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论:SEP-363856治疗精神分裂症的阴、阳性症状均有...本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物:SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论:SEP-363856治疗精神分裂症的阴、阳性症状均有效,且安全性、耐受性好,需要进一步扩大样本研究。The article introduces a novel antipsychotic drug, SEP-363856, approved by US FDA for clinical use in schizophrenia in 2020. A summary was made on the pharmacokinetics, receptor mechanism of action, clinical application, safety, and adverse reactions of the drug. Conclusion: SEP-363856 is effective in treating both negative and positive symptoms of schizophrenia and is safe and well tolerated. Further expansion of sample research is needed.展开更多
皮肌炎(dermatomyositis, DM)是一种主要累及骨骼肌和皮肤的自身免疫性疾病,常伴有特征性皮肤表现,继发或并发精神病性症状为临床少见。现报道一例DM继发精神病症状,在应用糖皮质激素基础上,联合小剂量抗精神病药物,获得良好效果的患者...皮肌炎(dermatomyositis, DM)是一种主要累及骨骼肌和皮肤的自身免疫性疾病,常伴有特征性皮肤表现,继发或并发精神病性症状为临床少见。现报道一例DM继发精神病症状,在应用糖皮质激素基础上,联合小剂量抗精神病药物,获得良好效果的患者,以提高临床医生对DM合并精神症状的认识水平。Dermatomyositis is an autoimmune disease that primarily affects skeletal muscle and skin, often accompanied by characteristic skin damage manifestations. Secondary or concurrent psychiatric symptoms are clinically rare. Now we report a patient with secondary psychiatric symptoms, who achieved good results in combination with low-dose antipsychotic drugs on the basis of glucocorticoids. The purpose is to improve the clinical doctors’ recognition level on DM combined with psychiatric symptoms.展开更多
文摘本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物:SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论:SEP-363856治疗精神分裂症的阴、阳性症状均有效,且安全性、耐受性好,需要进一步扩大样本研究。The article introduces a novel antipsychotic drug, SEP-363856, approved by US FDA for clinical use in schizophrenia in 2020. A summary was made on the pharmacokinetics, receptor mechanism of action, clinical application, safety, and adverse reactions of the drug. Conclusion: SEP-363856 is effective in treating both negative and positive symptoms of schizophrenia and is safe and well tolerated. Further expansion of sample research is needed.
文摘皮肌炎(dermatomyositis, DM)是一种主要累及骨骼肌和皮肤的自身免疫性疾病,常伴有特征性皮肤表现,继发或并发精神病性症状为临床少见。现报道一例DM继发精神病症状,在应用糖皮质激素基础上,联合小剂量抗精神病药物,获得良好效果的患者,以提高临床医生对DM合并精神症状的认识水平。Dermatomyositis is an autoimmune disease that primarily affects skeletal muscle and skin, often accompanied by characteristic skin damage manifestations. Secondary or concurrent psychiatric symptoms are clinically rare. Now we report a patient with secondary psychiatric symptoms, who achieved good results in combination with low-dose antipsychotic drugs on the basis of glucocorticoids. The purpose is to improve the clinical doctors’ recognition level on DM combined with psychiatric symptoms.
